TAIRE subfamily

Home
Targets
Enzymes
Kinases (EC 2.7.x.x)
CMGC: Containing CDK, MAPK, GSK3, CLK families
Cyclin-dependent kinase (CDK) family
TAIRE subfamily

Unless otherwise stated all data on this page refer to the human proteins. Gene information is provided for human (Hs), mouse (Mm) and rat (Rn).

Enzymes

Targets of relevance to immunopharmacology are highlighted in blue

CDK14 (cyclin dependent kinase 14) Show summary »« Hide summary More detailed page go icon to follow link

Target Id

1967

Nomenclature

cyclin dependent kinase 14

Common abbreviation

CDK14

Previous and unofficial names

cell division protein kinase 14 | PFTAIRE protein kinase 1 | PFTAIRE1 | PFTK1

Genes

CDK14 (Hs), Cdk14 (Mm), Cdk14 (Rn)

Ensembl ID

ENSG00000058091 (Hs), ENSMUSG00000028926 (Mm), ENSRNOG00000007151 (Rn)

UniProtKB AC

O94921 (Hs), O35495 (Mm)

EC number

2.7.11.22

CDK15 (cyclin dependent kinase 15) Show summary »« Hide summary More detailed page go icon to follow link

Target Id

1968

Nomenclature

cyclin dependent kinase 15

Common abbreviation

CDK15

Previous and unofficial names

Genes

CDK15 (Hs), Cdk15 (Mm), Cdk15 (Rn)

Ensembl ID

ENSG00000138395 (Hs), ENSMUSG00000026023 (Mm), ENSRNOG00000022899 (Rn)

UniProtKB AC

Q96Q40 (Hs), Q3V3A1 (Mm)

EC number

2.7.11.22

CDK16 (cyclin dependent kinase 16) Show summary »« Hide summary More detailed page go icon to follow link

CDK17 (cyclin dependent kinase 17) Show summary »« Hide summary More detailed page go icon to follow link

CDK18 (cyclin dependent kinase 18) Show summary »« Hide summary More detailed page go icon to follow link

How to cite this family page

Database page citation:

TAIRE subfamily. Accessed on 25/04/2024. IUPHAR/BPS Guide to PHARMACOLOGY, http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=491.

Concise Guide to PHARMACOLOGY citation:

Alexander SPH, Fabbro D, Kelly E, Mathie AA, Peters JA, Veale EL, Armstrong JF, Faccenda E, Harding SD, Davies JA et al. (2023) The Concise Guide to PHARMACOLOGY 2023/24: Enzymes. Br J Pharmacol. 180 Suppl 2:S289-373.